课题基金 / 基金详情

Understanding the real-world adverse event risks of novel biosimilar drugs

Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
批准号：
486321
负责人：
Ho Martin K
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-12-01 至 2023-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486321&lang=en
关键词：
Auto-Immune Diseases Biologic Drugs Biosimilars Comparative Drug Safety Health Policy Pharmacoepidemiology

项目摘要

项目成果

Ho Martin K的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Biologics are newer drugs that are made by living organisms or cells. They have greatly improved outcomes for many medical conditions that were previously not well treated, such as auto-immune diseases, but have been associated with high costs. Now that t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fear of missing out: Drug availability in Canada compared to the USA
  • 批准号：
    493050
  • 项目类别：
  • 资助金额：
    $0.15万
  • 财政年份：
    2023
  • 负责人：
    Ho Martin K
  • 依托单位：
    University of Toronto
海外基金